Scientists warn of negative effects of Alzheimer's drugs. Scientists in the study expressed their concern about the insufficient results of clinical trials of two ‘revolutionary’ drugs.
Lecanemab, developed by the Japanese company Eisai and its American partner Biogen, and donanemab,. produced by the American company Lilly. These drugs can lead to a slowdown in cognitive decline, which clears the brain of a toxic protein, which is considered the main sign of Alzheimer’s disease.